{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:48:27Z","timestamp":1780091307264,"version":"3.54.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Only few studies have presented results from real\u2010world clinical use of Extended Half\u2010Life (EHL) products in children with haemophilia (CWH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To retrospectively examine real\u2010life experience with EHL factor VIII products use in CWH A, comparing with clinical experience from standard half\u2010life products (SHL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review of medical records of CWH A who have been prescribed EHL factor concentrates was conducted. All before\/after comparisons were performed with the Wilcoxon matched\u2010pairs signed\u2010ranks test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010three children with severe haemophilia A were enrolled in the study (3\u20136 years old:<jats:italic>n<\/jats:italic>\u00a0=\u00a04, 7\u201312 years old:<jats:italic>n<\/jats:italic>\u00a0=\u00a07 and 13\u201318 years old:<jats:italic>n<\/jats:italic>\u00a0=\u00a012). Median length of time that patients were treated with EHL products was 78\u00a0weeks. Median dosing interval was significantly lengthened from 2.3 to 3.5\u00a0days after switching from SHL to EHL concentrates. Mean trough FVIII levels were significantly increased from 2.3% to 4.1% after treatment with EHL products. Also, CWH A had a reduction of mean annual bleeding rate (ABR) and mean annual joint bleeding rate (AJBR) from 1 and .8 to .3 and .2, respectively, following treatment with EHL concentrates (ABR:<jats:italic>p<\/jats:italic>\u00a0=\u00a0.02, AJBR:<jats:italic>p<\/jats:italic>\u00a0=\u00a0.05). However, after switching to factor EHL, actual FVIII consumption, including bleeds, was significantly increased from 94\u00a0IU\/kg\/week to 118\u00a0IU\/kg\/week in CWH A. There was no inhibitor development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates the successful transition of 23 CWH A from SHL to EHL factor concentrates.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14576","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T15:00:08Z","timestamp":1651590008000},"page":"619-624","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical application of extended half\u2010life factor VIII in children with severe haemophilia A"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-3767","authenticated-orcid":false,"given":"Athina","family":"Dettoraki","sequence":"first","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Michalopoulou","sequence":"additional","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Mazarakis","sequence":"additional","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Saslis","sequence":"additional","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Stamati","sequence":"additional","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoey","family":"Kapsimali","sequence":"additional","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-0597","authenticated-orcid":false,"given":"Helen","family":"Pergantou","sequence":"additional","affiliation":[{"name":"Haemophilia Centre\/Haemostasis and Thrombosis Unit \u201cAghia Sophia\u201d Children's Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13215"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1571315"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718796429"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_2_10_6_1","first-page":"A660","article-title":"Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII","volume":"18","author":"Iorio A","year":"2015","journal-title":"Value Health"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12766"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.1984.tb02560.x","article-title":"Calculation of factor VIII in vivo recovery and half\u2010life","volume":"40","author":"Kjellman H","year":"1984","journal-title":"Scand J Haematol Suppl"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13193"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2021"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13953"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000885"},{"key":"e_1_2_10_15_1","first-page":"1","article-title":"The Australian experience with switching to extended half\u2010life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors\u2019 Organisation","volume":"00","author":"Brennan Y","year":"2020","journal-title":"Haemophilia"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13432"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13834"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13245"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13758"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13403"},{"issue":"10","key":"e_1_2_10_21_1","first-page":"39","article-title":"Real\u2010world analysis of dispensed international units of coagulation factor VIII and resultant expenditures for hemophilia A patients: a comparison between standard half\u2010life and extended half\u2010life products","volume":"27","author":"Chhabra A","year":"2018","journal-title":"Manag Care"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1005093"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14576","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T23:56:17Z","timestamp":1700524577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/hae.14576"],"URL":"https:\/\/doi.org\/10.1111\/hae.14576","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"2021-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}